BARD1 Life Sciences is a company focused on developing and commercializing non-invasive diagnostic tests for early detection of cancer. Its proprietary technology platform is based on tumor markers with potential diagnostic and therapeutic applications across multiple cancers. BARD1 pipeline of product candidates includes autoantibody tests for early detection of lung and ovarian cancers and a vaccine for the treatment of cancer.